Clinical Pharmacokinetics and Antiviral Activity of CC-31244, a Pan-genotypic, Potent Nonnucleoside NS5B Polymerase Inhibitor (NNI) for the Treatment of Hepatitis C

Conference Reports for NATAP

26th Conference of the Asian Pacific
Association for the Study of the Liver
2017 APASL, Feb 15-19
Shanghai, China


Clinical Pharmacokinetics and Antiviral Activity of CC-31244, a Pan-genotypic, Potent Nonnucleoside NS5B Polymerase Inhibitor (NNI) for the Treatment of Hepatitis C

	Reported by Jules Levin 2017 APASL, Shanghai Sam Lee, Ph.D.